Home

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

via Business Wire
  • Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
  • Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”

Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

Contacts